Focusing on the INDIVIDUAL
Cipherome’s goal is to optimize individual drug response.
Cipherome’s goal is to personalize drug treatment
Each person deserves the best medicine. Drugs that work for the majority of the population may not work for your patient. Serious side effects or adverse drug reactions (ADRs) occur in certain individuals, but not in others. These differences may be due to inherited factors.
Our goal is to revolutionize healthcare to enable equity for all patients. We believe that good quality treatment can and should be available to everyone regardless of age, race, or gender.
Understanding a patient’s genomic information gives us a lens into how medications are affecting the body.
Our unique patented platform combines many components, including genomics and clinical factors, to provide the best drug for your patient so patients will be assured knowing that they are receiving personalized care.
How We Do It
Because of inherited (genetic) makeup, some people process drugs more slowly or more quickly, and some not at all. This can be of primary consequence to drug efficacy in people and some studies have shown that ADRs are the 4th leading cause of preventable death(1). Other studies attribute 3-7% of hospital admissions to ADRs(2,3). We use the study of all genetic variants (genomics) and a person’s age, weight, chronic diseases, medications, etc. (clinical factors) to determine how a drug will affect a person to limit ADRs.
(1) Lazarou, Pomernanz and Corey 1999. (Hyperlink reference: https://www.ncbi.nlm.nih.gov/books/NBK67323/.)
(2) Lundkvist and Jönsson 2004 (Hyperlink reference: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1472-8206.2004.00239.x
(3) Bouvy, De Bruin and Koopmanschap 2015. (Hyperlink reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412588/.)
Cipherome’s Scientific Advisory Board
-
Ju Han Kim, MD, PhD
Dr. Kim is a cofounder and advisor of Cipherome, currently serving as a professor, and the director and founding chair of the Division of Biomedical Informatics at Seoul National University School of Medicine.
-
Edward McCabe, MD, PhD
Dr. McCabe served as chair of the Department of Pediatrics and Professor at UCLA School of Medicine and is now a Distinguished Professor Emeritus. He has extensive genetics experience, including as American Society of Human Genetics President.
-
Robert Nied, MD
Dr. Nied is a practicing clinician at Kaiser Permanente with over 20 years of experience. He specializes in Sports Medicine and is currently delivering care to patients and athletes in San Francisco Mission Bay.
-
Todd Rich, MD, MBA
Dr. Rich most recently served on the Genentech executive leadership team as the Senior Vice President of Development Operations (drug safety, regulatory, health economics, medical information) and Quality at Genentech.
About Us
Cipherome is an AI and bioinformatics company focused on personalizing medications to limit ADRs using patented genomic technology.
Our team brings extensive experience in medicine, drug development, bioinformatics, AI, and award-winning product development to address a $136B market opportunity.
Cipherome has initiated clinical validation studies in cardiology, oncology, and gastroenterology with leading U.S., European and South Korean academic institutions to demonstrate clinical applications of the Xentinel® platform.
We are headquartered in San Jose, CA, the Capital of Silicon Valley, and have a research office located in Seoul, South Korea.
